Acceleron Pharma — JP Morgan Healthcare Conference 2018
29 slides from Acceleron Pharma's conference presentation, Jan 8, 2018
Slide 1: JP Morgan Healthcare Conference January 2018
JP Morgan Healthcare Conference January 2018 Exhibit 99.1
Slide 2: Acceleron Forward-Looking Statements
Acceleron Forward-Looking Statements 2 THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS and prospects, including statements regarding the development of the Company's compounds, the timeline for clinical development and regulatory approval of the Compa
Slide 3: Our mission is to transform the lives of patients with serious and rare diseases
3 Our mission is to transform the lives of patients with serious and rare diseases
Slide 4: Harnessing the Power of TGF-Beta Biology: Strategic Focus in Three Therapeutic Areas
MUSCLE PULMONARY Harnessing the Power of TGF-Beta Biology 4 TGF-Beta HEMATOLOGY Strategic Focus in Three Therapeutic Areas Growth Repair Differentiation C E L L U L A R :
Slide 5: High Unmet Medical Need Across Therapeutic Area Focus
High Unmet Medical Need Across Therapeutic Area Focus HEMATOLOGY NEUROMUSCULAR PULMONARY MDS / Thalassemia / MF FSHD / CMT PAH No approved anemia therapies RBC transfusions + off-label meds Focal muscle disease Physical therapy and bracing Multiple drugs approved, yet still only 5-7 year s
Slide 6: Our Vision
Our Vision 6 Leader in neuromuscular and pulmonary Complement in-house research portfolio success with BD efforts to drive therapeutic area leadership Drive life-cycle management Potential multi-billion $ asset Leader in chronic anemia HEMATOLOGY Develop first-in/best-in class assets NEUROMUSCULAR P
Slide 7: Building Therapeutic Area Leadership
Building Therapeutic Area Leadership Phase 1 Myelodysplastic Syndromes (MDS) Beta-Thalassemia FSH Dystrophy Neuromuscular Disease Preclinical Phase 2 Phase 3 Product Hematology Luspatercept Sotatercept ACE-2494 Neuromuscular ACE-083 MEDALIST Phase 3 COMMANDS Phase 3 (Planned) BELIEVE Phase 3 Phase 2
Slide 8: Hematology: Luspatercept
Sys se nies re Hematology: Luspatercept
Slide 9: Chronic Anemia Due to Rare Blood Disorders
Chronic Anemia Due to Rare Blood Disorders BETA-THALASSEMIA Genetic hemoglobin mutation MYELOFIBROSIS Fibrotic bone marrow disease LOWER-RISK MDS Bone marrow failure disorder CHRONIC ANEMIA 9
Slide 10: High Need for RBC Transfusion Reduction/Elimination
High Need for RBC Transfusion Reduction/Elimination 10 Reduces quality of life Negatively impacts progression and survival Inconvenient – 3 to 5 hours every 2 to 3 weeks Causes high spikes and low troughs in Hb levels Human derived product Potential iron overload
Slide 11: Luspatercept Treatment Goals
Increase and maintain ↑ hemoglobin levels Reduce or eliminate RBC transfusion burden LUSPATERCEPT TREATMENT GOALS: 11
Slide 12: Non-EPO Driven/Ineffective Erythropoiesis Chronic Anemias
Non-EPO Driven/Ineffective Erythropoiesis Chronic Anemias 12 EPO: erythropoietin Erythropoiesis-stimulating agent Erythroid maturation agent (EMA) Luspatercept-responsive 1 2 3 4 5 6 7 EPO-dependent ESA Luspatercept Hemoglobin (Hb) production
Slide 13: Multiple Phase 2 and Phase 3 Trials Ongoing and Planned
Multiple Phase 3 and Phase 2 Trials Ongoing and Planned 13 Lower-risk MDS PHASE 2 Beta-thalassemia Myelofibrosis First-line / ESA Naive RS+ ESA Refractory / Ineligible Non-Transfusion-Dependent Transfusion-Dependent Monotherapy / Combination PHASE 2
Slide 14: MDS Trials Supported by Luspatercept
MDS Trials Supported by Luspatercept Phase 2 Results 14 Lower-risk MDS First-line / ESA Naïve RS+ ESA Refractory / Ineligible 55%1 39%2 RBC Transfusion Independence 1. ASH 2017: ESA naïve LR MDS patients, RBC-TI: 17/31 or 55% 2. ASH 2015: RS+ LR MDS patients, RBC-TI: 12/31 or 39% RBC Transfusion Ind
Slide 15: Beta-Thalassemia Trials Supported by Luspatercept
Beta-Thalassemia Trials Supported by Luspatercept Phase 2 Results 15 Beta-thalassemia Non-Transfusion-Dependent Transfusion-Dependent 52%1 41%2 Increase in Mean Hb ≥ 1.5 g/dL 1. EHA 2017: NTD patients, ≥ 1.5 g/dL, 16/31 or 52%, over a 12-week period on treatment versus baseline 2. EHA 2017: TD patie
Slide 16: MF Trial Supported by Sotatercept
MF Trial Supported by Sotatercept Phase 2 MD Anderson IST Results 16 Myelofibrosis Monotherapy 39%1 30%2 Anemia Response 1. ASH 2017: sotatercept, 7/18 or 39% of evaluable patients 2. ASH 2017: sotatercept, 3/10 or 30% of evaluable patients Combination Therapy Anemia Response Phase 2 Results
Slide 17: Building a Potential Multi-Billion Dollar Anemia Brand
>40K PATIENTS MDS (RS+) ESA Experienced/Ineligible NTD Beta-Thalassemia >20K PATIENTS Myelofibrosis >15K PATIENTS >20K PATIENTS TD Beta-Thalassemia MDS First-line >20K PATIENTS ADDRESSABLE US/EU PATIENT POPULATION POTENTIAL NEW INDICATION >115K Building a Potential Multi-Billion Dollar Anemia Brand
Slide 18: Long-Term Durability of Response
Long-Term Durability of Response (Ongoing Phase 2 Trials) 18 MDS MF 3 YEARS 2 YEARS 1 YEAR Median1 19 Months Median2 14.2 Months Median3 -thal 1. ASH 2017: Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study 2. EHA
Slide 19: Collaborating with the Leader in Hematology
Collaborating with the Leader in Hematology 19 PROGRAM COSTS 100% Celgene funded WORLDWIDE ROYALTY Low- to mid-20% MILESTONES $185M outstanding CO-PROMOTE North America Celebrating 10 years of partnership
Slide 20: Neuromuscular Disease
Neuromuscular Disease
Slide 21: Building a Neuromuscular Franchise with ACE-083 and ACE-2494
ACE-083 Local Agent Building a Neuromuscular Franchise with ACE-083 and ACE-2494 21 ACE-2494 Systemic Agent
Slide 22: ACE-083: A Locally-Acting Myostatin+ Therapy to Target Focal Muscle Disease
Administered into target muscle for concentrated effect ACE-083: A Locally-Acting Myostatin+ Therapy to Target Focal Muscle Disease 22 FSHD MYOPATHY 20,000 US patients CMT NEUROPATHY > 100,000 US patients
Slide 23: Preliminary Results for Phase 2 FSHD Study - Part 1
Preliminary Results for Phase 2 FSHD Study - Part 1, Cohorts 1 and 2 Pooled 23 N=11 N=12 % Ch an ge in T o tal M u sc le V o lu m e Tibialis Anterior Biceps Brachii 12.6% 13.2% 0 5 10 15 20 A b sol u te Ch an ge in F at F rac tio n Tibialis Anterior Biceps Brachii -5.3% -0.6% -10 -5 0 5 N=11 N=12 Sa
Slide 24: oD) ” © ) — fa) > Shas © < fe) £ S a.
oD) ” © ) — fa) > Shas © < fe) £ S a.
Slide 25: Building a Pulmonary Platform Starting with PAH
Building a Pulmonary Platform Starting with PAH 25
Slide 26: Sotatercept Profile and Preclinical Results in PAH
Sotatercept Profile and Preclinical Results in PAH SOTATERCEPT IS A TGF-BETA LIGAND TRAP Blocks activin restoring the BMP signaling pathway Phase 2 ready with ~400 patients of clinical experience Subcutaneous injection every three weeks Outperforms standard of care in preclinical animal mode
Slide 27: Where Could Sotatercept Fit in Treatment Paradigm?
Where Could Sotatercept Fit in Treatment Paradigm? 27 Endothelin Receptor Antagonists (ERAs) PDE-5 Inhibitors Prostacyclin Standard of Care Options MOA: Vasodilation + + + Goal: Significantly Extend Survival and Quality of Life with Disease Modifying Combination sGC Stimulators + SOTATERCEPT MOA: Va
Slide 28: Upcoming Corporate Priorities
Upcoming Corporate Priorities HEMATOLOGY Luspatercept – MEDALIST and BELIEVE Phase 3 trial top-line results expected in mid-2018 – Initiate the COMMANDS Phase 3 trial in 1H 2018 NEUROMUSCULAR ACE-083 – FSHD and CMT Part 1 of Phase 2 trial preliminary results from all dose-escalation cohorts in 2
Slide 29: Our Commitment to Late-Stage Milestones
Our Commitment to Late-Stage Milestones 29
Acceleron Pharma — JP Morgan Healthcare Conference 2018 on 6ix